Table 3.
Univariate Analysis of Risk Factors for Transplantation Outcomes, All Patients
| Patient and Graft Characteristic | NRM | Relapse | OS | CRFS | RFS | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex | .627 | .189 | .177 | |||||||
| Male | Reference | Reference | Reference | .293 | Reference | .071 | Reference | |||
| Female | .89 (.57–1.39) | .75 (.48–1.15) | .84 (.61–1.16) | .79 (.6–1.02) | .81 (.59–1.1) | |||||
| Donor/recipient sex match | .977 | .757 | .925 | .852 | .868 | |||||
| Female to male | 1 (.6–1.7) | 1.08 (.65–1.8) | 1.02 (.69–1.52) | .97 (.7–1.34) | 1.03 (.71–1.5) | |||||
| Other | Reference | Reference | Reference | Reference | Reference | |||||
| Age (years) | .014 | .287 | .002 | .158 | .002 | |||||
| 50–59 | Reference | Reference | Reference | Reference | Reference | |||||
| >60 | 1.72 (1.1–2.67) | 1.24 (.82–1.88) | 1.65 (1.19–2.28) | 1.2 (.93–1.55) | 1.6 (1.18–2.18) | |||||
| Donor | .004 | .355 | .057 | .526 | .092 | |||||
| Related | Reference | Reference | Reference | Reference | Reference | |||||
| Nonrelated | 1.81 (1.19–2.77) | .81 (.54–1.22) | 1.35 (.99–1.85) | .92 (.72–1.19) | 1.29 (.96–1.73) | |||||
| Diagnosis | .009 | .104 | .184 | .225 | .421 | |||||
| AML | Reference | Reference | Reference | Reference | Reference | |||||
| MDS | 1.75 (1.15–2.67) | .68 (.43–1.08) | 1.24 (.9–1.71) | 1.18 (.9–1.53) | 1.13 (.83–1.54) | |||||
| HCT-CI | .038 | .168 | .121 | .332 | .11 | |||||
| 0 | Reference | Reference | Reference | Reference | Reference | |||||
| 1–2 | 1.67 (.87–3.2) | .58 (.33–1.02) | 1.01 (.65–1.57) | .83 (.59–1.18) | .91 (.6–1.39) | |||||
| ≥3 | 2.07 (1.25–3.43) | .83 (.58–1.19) | 1.39 (.95–2.03) | 1.05 (.78–1.42) | 1.3 (.91–1.86) | |||||
| DRI | .872 | <.001 | <.001 | <.001 | <.001 | |||||
| Low/intermediate | Reference | Reference | Reference | Reference | Reference | |||||
| High | .94 (.54–1.63) | 3.27 (2.15–4.96) | 2.31 (1.64–3.24) | 1.86 (1.39–2.5) | 2.35 (1.7–3.26) | |||||
| HCT approach | .106 | .001 | .285 | <.001 | .13 | |||||
| CD34+ cell selection MAC | Reference | Reference | Reference | Reference | Reference | |||||
| Unmodified RIC | .69 (.45–1.07) | 1.96 (1.3–2.94) | 1.18 (.87–1.62) | 3.4 (2.61–4.43) | 1.26 (.93–1.69) | |||||
| HCT approach and HCT-CI | .089 | .009 | .084 | <.001 | .041 | |||||
| TCD and HCT-CI 0–2 | Reference | Reference | Reference | Reference | Reference | |||||
| TCD and HCT-CI ≥ 3 | 1.62 (.93–2.81) | 1.42 (.78–2.6) | 1.65 (1.07–2.53) | 1.56 (1.06–2.31) | 1.67 (1.11–2.51) | |||||
| RIC and HCT-CI 0–2 | .81 (.52–1.26) | 2.4 (1.53–3.77) | 1.46 (.93–2.28) | 4.01 (2.76–5.83) | 1.57 (1.03–2.4) | |||||
| RIC and HCT-CI ≥ 3 | 1.07 (.69–1.65) | 2.33 (1.48–3.66) | 1.74 (1.06–2.87) | 4.92 (3.26–7.43) | 1.81 (1.13–2.9) |
Abbreviations: NRM, non-relapse mortality; OS, overall survival, CRFS Chronic GVHD-Free, Relapse-Free Survival; D/R, donor/recipient; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; DRI, Disease-risk index; AML, acute myeloid leukemia.